onasemnogene abeparvovec 在人体组织中的 DNA、mRNA 与 SMN 蛋白分布
该研究分析了两名接受 onasemnogene abeparvovec 治疗的 SMA1 婴儿尸检组织,显示载体基因组和转基因在 CNS 及外周器官广泛分布,肝内载体基因组浓度较 CNS 组织高 300–1,000 倍,SMN 蛋白在运动神经元、脑、骨骼肌及多个外周器官可检出。
要点
- 静脉给予 AAV9 介导的 onasemnogene abeparvovec 后,载体 DNA 和 mRNA 在 CNS 与外周器官广泛分布。
- 肝内载体基因组浓度最高,较 CNS 组织高 300–1,000 倍。
- 治疗患者运动神经元、脑、骨骼肌及多个外周器官可检出 SMN 蛋白。
核心结论
- onasemnogene abeparvovec 静脉给药后在中枢神经系统实现有效分布、转导和表达,并在人体恢复 SMN 表达。
研究设计与样本
- 研究分析两名入组 III 期研究并接受 onasemnogene abeparvovec 的有症状 SMA1 婴儿的组织分布。
- 两名患者均死于与 onasemnogene abeparvovec 无关的呼吸系统并发症。
主要发现
- 两名患者中 onasemnogene abeparvovec DNA 和 mRNA 在外周器官和 CNS 广泛分布。
- 肝内载体基因组浓度最高,较 CNS 组织高 300–1,000 倍。
- 未治疗 SMA1 对照中 SMN 蛋白低,治疗患者运动神经元、脑、骨骼肌和多个外周器官中 SMN 蛋白清晰可检出。
- 一名患者运动功能改善,另一名在可观察到明显临床获益前死亡。
临床怎么用
- 静脉给予 onasemnogene abeparvovec 可遍布 CNS 并恢复 SMN 表达,支持其系统给药策略。
局限性
- 证据来自两名死亡婴儿的尸检组织,样本量有限。
- 两名患者均死亡,其中一名在可观察到明显临床获益前死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Spinal muscular atrophy type 1 (SMA1) is a debilitating neurodegenerative disease resulting from survival motor neuron 1 gene (SMN1) deletion/mutation. Onasemnogene abeparvovec (formerly AVXS-101) is a gene therapy that restores SMN production via one-time systemic administration. The present study demonstrates widespread biodistribution of vector genomes and transgenes throughout the central nervous system (CNS) and peripheral organs, after intravenous administration of an AAV9-mediated gene therapy. Two symptomatic infants with SMA1 enrolled in phase III studies received onasemnogene abeparvovec. Both patients died of respiratory complications unrelated to onasemnogene abeparvovec. One patient had improved motor function and the other died shortly after administration before appreciable clinical benefit could be observed. In both patients, onasemnogene abeparvovec DNA and messenger RNA distribution were widespread among peripheral organs and in the CNS. The greatest concentration of vector genomes was detected in the liver, with an increase over that detected in CNS tissues of 300-1,000-fold. SMN protein, which was low in an untreated SMA1 control, was clearly detectable in motor neurons, brain, skeletal muscle and multiple peripheral organs in treated patients. These data support the fact that onasemnogene abeparvovec has effective distribution, transduction and expression throughout the CNS after intravenous administration and restores SMN expression in humans.
引用
- Thomsen G, Burghes AHM, Hsieh C, et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat Med. 2021. PMID: 34608334. doi:10.1038/s41591-021-01483-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。